Chartwell Investment Partners LLC Lowers Position in PRA Health Sciences Inc (PRAH)

Chartwell Investment Partners LLC lowered its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 6.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,782 shares of the medical research company’s stock after selling 2,201 shares during the period. Chartwell Investment Partners LLC’s holdings in PRA Health Sciences were worth $2,985,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Wells Fargo & Company MN increased its holdings in shares of PRA Health Sciences by 55.8% in the third quarter. Wells Fargo & Company MN now owns 1,207,069 shares of the medical research company’s stock valued at $91,943,000 after purchasing an additional 432,449 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of PRA Health Sciences by 3.4% in the third quarter. Russell Investments Group Ltd. now owns 915,111 shares of the medical research company’s stock valued at $69,704,000 after purchasing an additional 29,771 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in shares of PRA Health Sciences by 5.7% in the third quarter. Ameriprise Financial Inc. now owns 834,034 shares of the medical research company’s stock valued at $63,528,000 after purchasing an additional 45,227 shares in the last quarter. Hood River Capital Management LLC increased its holdings in shares of PRA Health Sciences by 31.5% in the third quarter. Hood River Capital Management LLC now owns 815,141 shares of the medical research company’s stock valued at $62,089,000 after purchasing an additional 195,217 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of PRA Health Sciences by 52.8% in the second quarter. State Street Corp now owns 782,800 shares of the medical research company’s stock valued at $58,729,000 after purchasing an additional 270,530 shares in the last quarter. 97.15% of the stock is owned by institutional investors and hedge funds.

In other news, EVP David W. Dockhorn sold 72,850 shares of the business’s stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $90.83, for a total value of $6,616,965.50. Following the completion of the transaction, the executive vice president now owns 72,850 shares of the company’s stock, valued at approximately $6,616,965.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Linda Baddour sold 67,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $90.27, for a total transaction of $6,048,090.00. The disclosure for this sale can be found here. Insiders have sold a total of 212,700 shares of company stock valued at $19,282,021 in the last ninety days. Company insiders own 2.10% of the company’s stock.

A number of analysts have commented on PRAH shares. SunTrust Banks reaffirmed a “buy” rating and set a $101.00 target price on shares of PRA Health Sciences in a report on Friday, October 27th. BidaskClub raised shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 27th. Jefferies Group reaffirmed a “buy” rating and set a $95.00 target price on shares of PRA Health Sciences in a report on Thursday, October 26th. Barclays started coverage on shares of PRA Health Sciences in a report on Monday, December 11th. They set an “overweight” rating and a $94.00 target price for the company. Finally, Zacks Investment Research lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. PRA Health Sciences has a consensus rating of “Buy” and an average price target of $92.31.

Shares of PRA Health Sciences Inc (PRAH) opened at $88.90 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38. PRA Health Sciences Inc has a fifty-two week low of $57.72 and a fifty-two week high of $95.90. The company has a market cap of $5,630.00, a price-to-earnings ratio of 49.94, a price-to-earnings-growth ratio of 1.20 and a beta of 0.31.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/20/chartwell-investment-partners-llc-lowers-position-in-pra-health-sciences-inc-prah.html.

PRA Health Sciences Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply